BAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Booz Allen Hamilton Holding Corp (BAH) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock exhibits bearish technical indicators, mixed analyst sentiment, and limited immediate positive catalysts. While the company has shown some improvement in net income and EPS, the declining revenue and gross margin, coupled with the uncertainty surrounding government funding, suggest that waiting for more clarity or a better entry point might be prudent.
The technical indicators for BAH are bearish. The MACD is negatively expanding (-1.254), RSI is at 24.398 (neutral zone), and the moving averages are aligned in a bearish order (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 75.825. This suggests a downward trend in the short term.
Hedge funds and insiders are significantly increasing their buying activity, which could indicate confidence in the stock's long-term potential.
The company raised FY26 EPS guidance by 9%, showing some optimism in earnings growth.
Revenue declined by 10.19% YoY in Q3 2026, and gross margin dropped by 5.27%, signaling operational challenges.
The Department of Homeland Security shutdown and government funding uncertainties could negatively impact Booz Allen's contracts and revenue.
Analysts have mixed ratings, with several firms maintaining Hold ratings and highlighting limited topline visibility.
In Q3 2026, Booz Allen's revenue dropped by 10.19% YoY to $2.62 billion, while net income increased by 6.53% YoY to $198 million. EPS rose by 12.41% YoY to $1.63, but gross margin fell to 51.03%, down 5.27% YoY. This indicates cost management improvements but declining overall business performance.
Analyst sentiment is mixed. UBS raised the price target to $97 but maintained a Neutral rating. Stifel increased the price target to $115 but also kept a Hold rating. Jefferies noted a 9% EPS guidance increase but highlighted a 5%-6% revenue contraction. Truist raised the price target to $98, citing potential defense spending growth, but also maintained a Hold rating. BofA remains bearish with an Underperform rating and a $90 price target, citing uncertainties in the civil business and CFO transition.
